Health
Researchers develop ultrapotent miniproteins that target SARS-CoV-2 receptor-binding domain – News-Medical.Net
Researchers have investigated the effectiveness of a bioengineered miniprotein in protecting against SARS-CoV-2 infection in vivo. The researchers evaluated the…
Last September, researchers at the University of Washington, USA, reported the development of computer-designed small proteins – ‘miniproteins’ – that can target the receptor-binding domain (RBD) on the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic.
This work was published in the journal Science, claiming the lead antiviral miniprotein candidate, named LCB1, which exhibited better protective…
-
Business22 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
General22 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
Noosa News8 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General22 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts